Friday, May 8, 2026

Roche to acquire PathAI to expand AI-driven diagnostics

Roche announced on 7 May 2026 that it has signed a definitive merger agreement to acquire PathAI, a US company focused on digital pathology and AI-powered technologies for pathology laboratories and the biopharma industry. Once the transaction closes, PathAI is set to join Roche’s Diagnostics division.

The companies have been working together since 2021. In 2024, they expanded the collaboration to include the development of AI-enabled companion diagnostic algorithms. Closing is expected in the second half of the year, subject to customary conditions and regulatory approvals.

Digital pathology portfolio and lab workflows

Roche positions the acquisition as a step to strengthen its digital pathology offering. Digital pathology converts tissue on glass slides into high-resolution digital images, enabling software-based workflows and AI-supported analysis for pathologists.

A key asset is PathAI’s Image Management System marketed as AISight IMS. Roche plans to scale this platform globally, aiming to support laboratory workflow efficiency through integrated analysis and workflow features.

Boost for precision medicine and biopharma services

Roche also expects the combination to enhance its precision medicine and biopharma services capabilities. PathAI contributes AI-driven solutions, including support for clinical trials and translational research. Together with Roche’s companion diagnostics expertise, the company aims to accelerate biomarker discovery and the creation of new diagnostic tools.

Purchase price and timing

Under the agreement, Roche will pay an upfront purchase price of USD 750 million, with additional milestone payments of up to USD 300 million. The deal is subject to antitrust and other regulatory approvals, and closing is currently expected in the second half of the year.